Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia.

Schizophrenia research - 27 Jul 1998

Kapitany T, Meszaros K, Lenzinger E, Schindler S D, Barnas C, Fuchs K, Sieghart W, Aschauer H N, Kasper S

Abstract excerpt

In the present study, the occurrence of tardive dyskinesia (TD) in chronic schizophrenia patients was investigated in relation to pharmacogenetic polymorphisms. It is known that the metabolism of important neuroleptic drugs is influenced by polymorphisms of the CYP2D6 gene, which encodes the cytochrome P450 enzyme debrisoquine/spartein hydroxylase. Forty-five patients meeting the DSM IV criteria for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Antipsychotic Agents
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genotype

Share to Polymorphism, Genetic

Share to Schizophrenia

Source

Identifiers

PMID: 9713905
DOI: 10.1016/s0920-9964(98)00038-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia.PMID 9713905Read ↗

CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.Semantic proximity Read ↗

Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients.Semantic proximity Read ↗

Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia.Semantic proximity Read ↗

CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.Semantic proximity Read ↗

CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects.Semantic proximity Read ↗

CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.Semantic proximity Read ↗

CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis.Semantic proximity Read ↗

CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.Semantic proximity Read ↗

An association study of debrisoquine hydroxylase (CYP2D6) polymorphisms in schizophrenia.Semantic proximity Read ↗

Lack of association between debrisoquine 4-hydroxylase (CYP2D6) gene polymorphisms and schizophrenia.Semantic proximity Read ↗

Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients.Semantic proximity Read ↗

Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.